Previous 10 |
OncoCyte (NYSEMKT: OCX ) +132% on lung cancer liquid biopsy test results . More news on: OncoCyte Corporation, Voyager Therapeutics, Sanmina Corp, Stocks on the move, , Read more ...
Thinly traded micro cap Voyager Therapeutics (NASDAQ: VYGR ) is up 37% premarket on light volume in reaction to its out-licensing deal with Neurocrine Biosciences (NASDAQ: NBIX ) under which the latter will own development and commercialization rights to gene therapy programs f...
Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine Biosciences gains development and commercialization rights to gene therapy programs VY-AADC for Parkinson’s...
G1 Therapeutics (NASDAQ: GTHX ) resumed with Buy rating and $80 (31% upside) price target at BTIG Research. More news on: G1 Therapeutics, Voyager Therapeutics, MacroGenics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences: Wells ...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...